Brooklyn Investment Group Increases Stock Position in Danaher Co. (NYSE:DHR)

Brooklyn Investment Group boosted its holdings in shares of Danaher Co. (NYSE:DHR) by 5.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,911 shares of the conglomerate’s stock after purchasing an additional 249 shares during the quarter. Brooklyn Investment Group’s holdings in Danaher were worth $1,365,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. CarsonAllaria Wealth Management Ltd. acquired a new position in Danaher in the 2nd quarter valued at $25,000. nVerses Capital LLC acquired a new position in Danaher during the second quarter worth about $25,000. MidAtlantic Capital Management Inc. purchased a new position in Danaher in the 3rd quarter worth approximately $40,000. MFA Wealth Advisors LLC purchased a new stake in shares of Danaher in the second quarter valued at approximately $51,000. Finally, Financial Connections Group Inc. purchased a new position in Danaher during the second quarter worth approximately $51,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on DHR shares. Stephens reiterated an “overweight” rating and set a $315.00 price target on shares of Danaher in a report on Wednesday, October 23rd. Stifel Nicolaus raised their price target on shares of Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a report on Wednesday, October 23rd. Robert W. Baird cut their target price on Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a research note on Wednesday, October 23rd. UBS Group lowered their price target on Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a report on Wednesday, October 23rd. Finally, TD Cowen boosted their price objective on shares of Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a report on Wednesday, October 23rd. Six equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $287.16.

Danaher Stock Down 0.2 %

Shares of NYSE DHR opened at $237.11 on Tuesday. The stock has a market capitalization of $171.26 billion, a price-to-earnings ratio of 45.35, a price-to-earnings-growth ratio of 4.34 and a beta of 0.85. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. The firm has a 50-day moving average price of $257.38 and a 200 day moving average price of $259.93. Danaher Co. has a 52 week low of $215.68 and a 52 week high of $281.70.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.57 by $0.14. The business had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The business’s revenue was up 3.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.02 EPS. Equities research analysts anticipate that Danaher Co. will post 7.5 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, October 25th. Shareholders of record on Friday, September 27th were issued a $0.27 dividend. The ex-dividend date was Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.46%. Danaher’s dividend payout ratio (DPR) is 20.61%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.